Special Issues

Special Issue Title: Thrombosis: Clinical Diagnosis and Treatment

· Print Special Issue Flyer

· Deadline for manuscript submissions:  1 December 2020

Special Issue Editor

Guest Editor

        Dr. Raviteja R. Guddeti

        Minneapolis Heart Institute, USA

Website | E-Mail

Interests: Cardiology; Interventional Cardiology

Special Issue Information

Dear Colleagues,

Thrombosis, defined as the formation of blood clots within the vasculature leading to complete or partial obstruction to blood flow in the vessel, is one of the leading causes of morbidity and mortality in the developed world. It can be both arterial and venous and encompasses a wide variety of diagnoses including the more common myocardial infarction, cerebrovascular accident, acute limb ischemia, deep vein thrombosis/pulmonary embolism to the rare anti-phospholipid syndrome and heparin-induced thrombocytopenia and thrombosis. The incidence and prevalence of thrombosis depend on whether it is arterial or venous. Both forms of thrombosis are associated with poor prognosis with long-term sequelae contributing significantly to the healthcare burden.

The pathophysiology of arterial and venous thrombosis is different and management requires a thorough understanding of the underlying pathophysiology and the location of the thrombus (arterial or venous). Over the years treatment strategies for the management of thrombosis have changed significantly, especially with the advent of newer drugs. While antiplatelet agents are the first choice of drugs for the management of arterial thrombosis, vitamin K antagonists and direct oral anticoagulants are preferred for venous thrombosis. Also, adjunct therapies such as catheter-directed thrombolysis, thrombectomy, and stenting have shown to be efficacious in certain clinical settings.

The topic of ‘Thrombosis’ will be explored further in this special issue of Reviews in Cardiovascular Medicine. We sincerely invite our esteemed colleagues to submit original articles and reviews on the topic “Thrombosis: Clinical Diagnosis and Treatment” with special emphasis on pathophysiology, diagnosis, and treatment strategies, including novel therapies. We believe this issue will help provide practicing clinicians and clinicians-in-training a detailed synopsis of the management of various disorders associated with thrombosis and also form a suitable framework for further research in this field.

Dr. Raviteja R. Guddeti

Guest Editor


Manuscript Submission Information

Manuscripts should be submitted online at https://rcm.imrpress.org by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Reviews in Cardiovascular Medicine is an international peer-reviewed open access quarterly journal published by IMR Press.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is $1950. Submitted papers should be well formatted and use good English.


Thrombosis; Anticoagulation; Myocardial infarction; Cerebrovascular accident; Acute limb ischemia; Deep vein thrombosis/pulmonary embolism

Share This Special Issue


Please wait a minute...
For Selected: Toggle Thumbnails
Platelet reactivity in dyslipidemia: atherothrombotic signaling and therapeutic implications
Moua Yang, Andaleb Kholmukhamedov
Reviews in Cardiovascular Medicine    2021, 22 (1): 67-81.   DOI: 10.31083/j.rcm.2021.01.256
Abstract324)   HTML44)    PDF(pc) (1824KB)(509)       Save
The risks for adverse thrombotic events, including myocardial infarction, stroke, and deep vein thrombosis, are markedly increased in dyslipidemia and other metabolic disorders and are the major cause of death worldwide. Recent evidence points out that increased thrombotic risk in dyslipidemia is mediated by platelets circulating in a pre-activated state. The mechanisms of platelet reactivity in this setting are multifaceted including platelet activation by classic agonist receptor signaling as well as platelet sensitization by pattern recognition receptors. Elevated platelet counts in dyslipidemia due to dysregulation in hematopoiesis also contribute to the overall thrombotic phenotype. Despite recent advancements in antiplatelet and anticoagulation therapies, recurrences of adverse thrombotic events remain to be a large clinical burden. In the light of new knowledge, understanding mechanisms that drive pathologic thrombosis in dyslipidemia, the antithrombotic approach shall be revisited. Here, we discuss potential therapeutic avenues based on the overview of platelet signaling mechanisms that contribute to a prothrombotic phenotype in dyslipidemia.
Related Articles | Metrics

Current Issue

  • Volume 22, Issue 3